Skip to content
type1.science
Phase 3Not yet recruitingNCT07211802

CKM for safer SGLT2 inhibitor use in type 1 diabetes

UC San Diego randomized crossover study asking whether a dual continuous glucose-ketone monitor can reduce ketone exposure while adults with type 1 diabetes take low- or high-dose sotagliflozin.

Primary endpoints

  • Time with beta-hydroxybutyrate above 0.6 mmol/L during 6-week treatment periods

Results so far

No results posted yet.